Alerta De Seguridad para ARCHITECT STAT High Sensitive Troponin-I Assay

Según Department of Health, este evento ( alerta de seguridad ) involucró a un dispositivo médico en Hong Kong que fue producido por Abbott.

¿Qué es esto?

Las alertas proporcionan información importante y recomendaciones sobre los productos. Aunque se haya emitido una alerta, esto no significa necesariamente que el producto se considera peligroso. Las alertas de seguridad, dirigidas a trabajadores de la salud y a usuarios, pueden incluir retiro de equipos. Pueden ser escritas por los fabricantes, pero también por funcionarios del área de salud.

Más información acerca de la data acá
  • Tipo de evento
    Safety alert
  • Fecha
    2016-05-03
  • Fecha de publicación del evento
    2016-05-03
  • País del evento
  • Fuente del evento
    DH
  • URL de la fuente del evento
  • Notas / Alertas
    Hong Kong data is current through September 2018. All of the data comes from the Department of Health (Hong Kong), except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Hong Kong.
  • Notas adicionales en la data
    Medical Device Safety Alert
  • Causa
    Medical device safety alert: abbott architect stat high sensitive troponin-i assay medical device manufacturer, abbott, has issued a medical device safety alert concerning its architect stat high sensitive troponin-i assay. the manufacturer is informing affected users of a product recall and reduced expiration dating for select architect stat high sensitive troponin-i reagent lots. predictive quality assurance monitoring of architect stat high sensitive troponin-i reagent lots was initiated following the field action that occurred in january (fa21jan2016). as a result, the manufacturer has identified a potential for increased calibration failures prior to the expiration date. according to the manufacturer, there is a potential for delay in results due to calibration errors and failure to calibrate. nonetheless, there is no impact to generated patient results. manufacturer will continue to monitor performance of all on-market lots. until root cause is determined and corrective actions are implemented, new reagent lots will have a proactively shortened expiration date of 4 months from date of manufacture. the expiration date will require adjustments to the laboratory inventory and order management practices. affected users are instructed either: to destroy any remaining inventory of affected lots once an alternate reagent lot is available, or to adjust the expiration date of the affected lots according to the local supplier, the affected products are distributed in hong kong. if you are in possession of the affected products, please contact your supplier for necessary actions. posted on 3 may 2016.

Device

  • Modelo / Serial
  • Descripción del producto
    Medical Device Safety Alert: Abbott ARCHITECT STAT High Sensitive Troponin-I Assay
  • Manufacturer

Manufacturer

  • Empresa matriz del fabricante (2017)
  • Comentario del fabricante
    “We are in constant communication with regulatory agencies and competent authorities worldwide which allows us to implement global recalls or in-country communication quickly and effectively,” Abbott, which now owns St. Jude Medical told ICIJ in a statement. In addition to sending global notices to physicians worldwide, we also make sure that product advisories are available online and classification of product recalls and product advisories are determined by global regulatory bodies which can impact the timing in any given country. MD companies follow varying regulations in different countries. In come countries software is not regulated so a recall in one country related to software would not be classified as a recall or field action in another. In addition, review cycles within the regulatory process can be different in each country which can impact communication and recall timing.
  • Source
    DH